A5043064006- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Neuroendocrine Tumor Research Advances
- HIV/AIDS drug development and treatment
- Growth Hormone and Insulin-like Growth Factors
- Testicular diseases and treatments
- Cancer Risks and Factors
- HIV-related health complications and treatments
- HIV, Drug Use, Sexual Risk
- Chronic Lymphocytic Leukemia Research
- Bacterial Identification and Susceptibility Testing
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Antimicrobial Resistance in Staphylococcus
- Hepatitis C virus research
- Thyroid Disorders and Treatments
- CAR-T cell therapy research
- Antibiotic Use and Resistance
- Hepatitis B Virus Studies
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Polyomavirus and related diseases
Institut de Recherche pour le Développement
2021
Economic & Social Sciences, Health Systems & Medical Informatics
2021
Hôpital Sainte-Marguerite
2021
Aix-Marseille Université
2021
Inserm
2021
Assistance Publique Hôpitaux de Marseille
2021
University of Toronto
2021
Novartis (Switzerland)
2006
Norton Healthcare
2006
Herlev Hospital
2006
Dalbavancin, a novel glycopeptide with long elimination half-life (∼9–12 days), was compared to standard antimicrobial therapy for skin and soft-tissue infections (SSTIs). In randomized, controlled, open-label, phase 2 proof-of-concept trial, adults received 1100 mg of dalbavancin (as single intravenous infusion), 1000 intravenously then 500 1 week later, or prospectively defined standard-of-care regimen. A gram-positive pathogen isolated from samples obtained 41 (66%) 62 patients at...
Abstract Objectives To analyse the occurrence of virological failure (VF) in patients starting ART with an integrase strand transfer inhibitor (INSTI)-based regimen recent years, relation previous episodes low-level viral load (LLVL). Patients and methods a first between 1 January 2015 31 December 2020 based on two NRTIs one INSTI were included if after control (two measures VL < 50 copies/mL) they had minimum additional measurements. Cox models adjusted for sex, age, acquisition...
The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency (HIV)-HCV-coinfected patients are deemed priority population for HCV elimination, while rise recently acquired infections men who have sex with (MSM) has been described. We describe the variations HIV-HCV epidemiology French Dat'AIDS cohort.This was retrospective analysis prospective cohort persons living HIV (PLWH)...
7104 Background: Based on its activity in a wide range of tumors including those that are taxane resistant, the novel microtubule stabilizer patupilone (EPO906; epothilone B) has potential to treat NSCLC. Fifty patients were enrolled phase I evaluate safety, efficacy, and optimal dose. The II part this study is investigating antitumor 53 with stage IIIB/IV Methods: Patients histologically or cytologically confirmed unresectable, locally advanced, metastatic NSCLC documented before 1st-line...
Aspirational targets to end AIDS by 2030 include having 95% of people with human immunodeficiency virus (HIV; PWH) diagnosed, treated, and controlled viral load (VL). Our objective was describe, using a large French prospective cohort, the median transition times through cascade care between 2009 2019. We analyzed patients whose first HIV diagnosis made 1 January 31 December Using Kaplan-Meier method, we estimated time linkage (from biological assessment), treatment (date antiretroviral...
Abstract Although antiretroviral treatment (ART) suppresses HIV RNA in blood and prevents transmission, low-level anorectal shedding persists some ART-treated men who have sex with men. We collected biopsies swabs from 55 on effective ART, hypothesizing that would be linked to microbiota-driven mucosal T cell activation. Lymphocytes were assessed by flow cytometry, soluble immune factors multiplex immunoassay, neutrophils epithelial integrity immunofluorescence microscopy, the microbiome...